Study: Pfizer’s Paxlovid COVID Pill Showed No Measurable Benefit In Adults 40 To 65

Study: Pfizer’s Paxlovid COVID Pill Showed No Measurable Benefit In Adults 40 To 65

Pfizer’s COVID pill reportedly offered no measurable benefit for adults 40 to 65, according to a study published on Wednesday.

The Israeli study was conducted among 109,000 patients who were 40 years old or older.

READ MORE
 

Study: Pfizer’s Paxlovid COVID Pill Showed No Measurable Benefit In Adults 40 To 65

Study: Pfizer’s Paxlovid COVID Pill Showed No Measurable Benefit In Adults 40 To 65

U.S.–Iran Nuclear Talks Resume as Moment of Truth Nears in the Middle East

After weeks of uncertainty, the United States and Iran are once…
Read more
Study: Pfizer’s Paxlovid COVID Pill Showed No Measurable Benefit In Adults 40 To 65

U.S. and Iran Resume High-Stakes Nuclear Talks in Oman Amid Rising Regional Tensions

The United States and Iran resumed nuclear negotiations…
Read more